A systematic review and meta-analysis including studies in NSCLC, RCC, and UC showed that PD-1 inhibitors exhibited a superior OS and PFS compared with PD-L1 inhibitors [88]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.